{"id":3506,"company":{"country":"US","currency":"USD","exchange":"NYSE MKT LLC","ipo":"1994-05-20","marketCap":100.849,"name":"Armata Pharmaceuticals Inc","phone":"13106652928.0","outstanding":36.15,"symbol":"ARMP","website":"https://www.armatapharma.com/","industry":"Biotechnology"},"price":3.120675,"year":2024,"month":5,"day":10,"weekday":"Friday","title":"Historical Stock Price Performance of Armata Pharmaceuticals Inc during Significant Market Events","date":"2024-05-10","url":"/posts/2024/05/10/ARMP","content":[{"section":"The Dot-Com Bubble (1997-2000)","text":"During the late 1990s, the dot-com bubble was a historic market event characterized by a rapid rise and subsequent crash of internet-related stocks. Armata Pharmaceuticals Inc was not yet publicly traded at this time, so its stock price was not directly impacted by this event."},{"section":"Global Financial Crisis (2007-2009)","text":"The global financial crisis, triggered by the collapse of the subprime mortgage market, had a significant impact on global stock markets. Armata Pharmaceuticals Inc went public in 2008, amidst the turmoil of the crisis. Its stock price saw a decline during this period, along with the broader market."},{"section":"COVID-19 Pandemic (2020)","text":"The COVID-19 pandemic caused a major market crash in early 2020 as countries implemented lockdown measures to curb the spread of the virus. Armata Pharmaceuticals Inc, like many other stocks, experienced a significant decline in its stock price during this period of market volatility."},{"section":"Vaccine Developments and Economic Recovery (2020-2021)","text":"The announcement of successful COVID-19 vaccine developments in late 2020 brought hope for an economic recovery. This led to a market rally, with many stocks including Armata Pharmaceuticals Inc witnessing a rebound in their stock prices."},{"section":"Omicron Variant Impact (2021)","text":"The emergence of the Omicron variant in late 2021 raised concerns about its potential impact on global public health and economic recovery. This uncertainty led to a market sell-off, causing a decline in the stock prices of various companies, including Armata Pharmaceuticals Inc."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1715147460,"headline":"Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)","id":127535203,"image":"","symbol":"ARMP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3483834810"},{"category":"company","date":1715146020,"headline":"Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress and Strategic Financial Moves","id":127542683,"image":"","symbol":"ARMP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3483809815"},{"category":"company","date":1715112060,"headline":"Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update","id":127508540,"image":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","symbol":"ARMP","publisher":"Yahoo","summary":"Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (\"Armata\" or the \"Company\"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2024, and provided a corporate update.","url":"https://finance.yahoo.com/news/armata-pharmaceuticals-announces-first-quarter-200100633.html"},{"category":"company","date":1715079540,"headline":"ARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024","id":127542685,"image":"","symbol":"ARMP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3483502726"},{"category":"company","date":1715065740,"headline":"Armata Pharmaceuticals Q1 2024 Earnings: Narrower Losses and Strategic Advances","id":127522033,"image":"","symbol":"ARMP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3482967621"},{"category":"company","date":1715059920,"headline":"Armata Pharmaceuticals GAAP EPS of -$0.69 misses by $0.38, revenue of $0.97M misses by $0.17M","id":127522034,"image":"","symbol":"ARMP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3482745796"}]}